Mean Platelet Volume to Lymphocyte Ratio: A New Biomarker Predicting Response in Patients with Solid Tumors Treated with Nivolumab

Basit Öğe Kaydı
dc.contributor.authorYildirim, H.C.
dc.contributor.authorKus, F.
dc.contributor.authorGuven, D.C.
dc.contributor.authorKaraca, E.
dc.contributor.authorKaygusuz, Y.
dc.contributor.authorDizdar, O.
dc.contributor.authorAksoy S.
dc.date.accessioned2024-05-19T14:33:29Z
dc.date.available2024-05-19T14:33:29Z
dc.date.issued2023
dc.departmentİstinye Üniversitesien_US
dc.description.abstractIntroduction: Although immune checkpoint inhibitors (ICIs) are widely used in cancer treatment, identifying factors that predict treatment response remains a challenge in clinical practice. There is a need for biomarkers to identify patients who may not benefit from these treatments. It is crucial to identify a simple and cost-effective biomarker that can be easily incorporated into clinical practice. This study aims to investigate the mean platelet volume to lymphocyte ratio (MPVLR), as measured by a hemogram test, and median overall survival (mOS) in patients with cancer treated with nivolumab. Methods: A total of 131 adult patients with metastatic cancer, including malignant melanoma (MM), renal cell carcinoma (RCC), non–small cell lung cancer (NSCLC), and head and neck cancer (HNC), were included in this study. Baseline demographics, ECOG (Eastern Cooperative Oncology Group) performance status, tumor type, and blood count parameters were recorded. Univariate and multivariate analyses were conducted to evaluate potential risk factors. Results: The median age of the patients was 59.87 ± 11.97 years, and the median follow-up period was 20.20 months (IQR, 12.80–27.60). RCC (43.5%) and MM (25.9%) were the most common diagnoses. Patients with ECOG scores of 0–1 had a longer mOS than those with scores of 2–3 (mOS: 20.60 months [95% CI, 14.94–25.29] vs. 5.24 months [95% CI, 0–16.42], p < 0.001). Additionally, patients with lactate dehydrogenase (LDH) levels within the normal range had a longer mOS than those with high LDH levels (mOS: 24.54 months [95% CI, 14.13–34.96] vs. 13.10 months [95% CI, 4.49–21.72], p = 0.038). Patients with low MPVLR also had a longer mOS than those with high MPVLR (mOS: 33.70 months [95% CI, 25.99–41.42] vs. 11.07 months [95% CI, 6.89–15.24], p < 0.001). In the multivariate Cox regression analysis, high MPVLR, ECOG score of 2–3, and high LDH level were associated with shorter mOS (p < 0.001, p = 0.001, and p = 0.046, respectively). Conclusion: This study demonstrates that MPVLR could serve as a novel biomarker for predicting response to nivolumab treatment. Incorporating MPVLR into clinical practice may aid in identifying patients who are less likely to benefit from the treatment. © 2023, Innovative Healthcare Institute. All rights reserved.en_US
dc.identifier.doi10.36401/JIPO-23-3
dc.identifier.endpage176en_US
dc.identifier.issn2666-2345
dc.identifier.issue4en_US
dc.identifier.scopus2-s2.0-85178957407en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage170en_US
dc.identifier.urihttps://doi.org/10.36401/JIPO-23-3
dc.identifier.urihttps://hdl.handle.net/20.500.12713/4248
dc.identifier.volume6en_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherInnovative Healthcare Instituteen_US
dc.relation.ispartofJournal of Immunotherapy and Precision Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmz20240519_kaen_US
dc.subjectBiomarkeren_US
dc.subjectİmmunotherapyen_US
dc.subjectMean Platelet Volume To Lymphocyte Ratioen_US
dc.subjectNivolumaben_US
dc.titleMean Platelet Volume to Lymphocyte Ratio: A New Biomarker Predicting Response in Patients with Solid Tumors Treated with Nivolumaben_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu